Clinical trial
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV…
NCT00255762 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00255762 |
|---|---|
| Title | Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery |
| Official title | Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients With Unresectable Stage IV Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Biological, Drug, Other |
| Interventions | carboplatin, paclitaxel, bevacizumab, laboratory biomarker analysis |
| Enrollment | 47 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2006 |
| First posted | Nov 21, 2005 |
| Last update posted | Oct 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: